What is the official website of Novartis Nederland - Oncologie ?

The official website of Novartis Nederland - Oncologie is https://www.zorgverlener.novartis.nl/therapeutische-gebieden/oncologie.

What is Novartis Nederland - Oncologie's cybersecurity risk score?

Novartis Nederland - Oncologie has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Nederland - Oncologie experienced?

According to Rankiteo, Novartis Nederland - Oncologie currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Nederland - Oncologie been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Nederland - Oncologie has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Nederland - Oncologie have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Nederland - Oncologie is not certified under SOC 2 Type 1.

Does Novartis Nederland - Oncologie have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Nederland - Oncologie does not hold a SOC 2 Type 2 certification.

Does Novartis Nederland - Oncologie comply with GDPR ?

According to Rankiteo, Novartis Nederland - Oncologie is not listed as GDPR compliant.

Does Novartis Nederland - Oncologie have PCI DSS certification ?

According to Rankiteo, Novartis Nederland - Oncologie does not currently maintain PCI DSS compliance.

Does Novartis Nederland - Oncologie comply with HIPAA ?

According to Rankiteo, Novartis Nederland - Oncologie is not compliant with HIPAA regulations.

Does Novartis Nederland - Oncologie have ISO 27001 certification ?

According to Rankiteo,Novartis Nederland - Oncologie is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Nederland - Oncologie operate in ?

Novartis Nederland - Oncologie operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Nederland - Oncologie have ?

Novartis Nederland - Oncologie employs approximately None employees people worldwide.

Does Novartis Nederland - Oncologie own any subsidiaries ?

Novartis Nederland - Oncologie presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Nederland - Oncologie have ?

Novartis Nederland - Oncologie's official LinkedIn profile has approximately 1,874 followers.

What is the NAICS classification code for Novartis Nederland - Oncologie ?

Novartis Nederland - Oncologie is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Nederland - Oncologie have a Crunchbase profile ?

No, Novartis Nederland - Oncologie does not have a profile on Crunchbase.

Does Novartis Nederland - Oncologie have a LinkedIn profile ?

Yes, Novartis Nederland - Oncologie maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-nederland-oncologie.

How many cybersecurity incidents has Novartis Nederland - Oncologie experienced ?

As of July 18, 2026, Rankiteo reports that Novartis Nederland - Oncologie has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Nederland - Oncologie have ?

Novartis Nederland - Oncologie has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Nederland - Oncologie faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NNO

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Novartis Nederland - Oncologie Vendor Cyber Rating & Cyber Score

novartis.nl

Add Your Compliance Badge

Novartis Oncologie ontwikkelt een portfolio met gepatenteerde geneesmiddelen op het gebied van oncologie, hematologie en zeldzame aandoeningen om mensen met kanker en aanverwante ziekten zo goed mogelijk te behandelen. De richtlijnen van onze LinkedIn pagina kan je terugvinden op https://www.novartis.nl/sites/www.novartis.nl/files/linkedin-community-guidelines-NL.pdf

NNO A.I CyberSecurity Scoring

Scoring History

NNO

Novartis Nederland - Oncologie CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Nederland ...

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

NNO Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NNO

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Oncologie in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Nederland - Oncologie in 2026.

Incident Types NNO vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Oncologie in 2026.

Incident History - NNO (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Nederland - Oncologie Subsidiaries

NNO

Pharmaceutical Manufacturing

Website: https://www.zorgverlener.novartis.nl/therapeutische-gebieden/oncologie

Company Size: 10,001+ employees

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Loading…

Novartis Nederland - Oncologie Similar Companies

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Loading…

NEWS

Novartis Nederland - Oncologie CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-57980

SUMMARY

Authentication bypass using an alternate path or channel in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform tampering over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-57980

CVE-2026-56741

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not apply an upper bound to terminal dimensions received via the Telnet NAWS option, and TelnetIO.handleNAWS() in TelnetIO.java:856-879 reads client-supplied width and height as 16-bit unsigned integers and passes values such as 65535x65535 to setTerminalGeometry(), allowing an unauthenticated remote attacker to repeatedly alternate values and trigger continuous expensive rendering work that causes CPU exhaustion and denial of service. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56740

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not limit the number of environment variables a client may inject via the Telnet NEW-ENVIRON option, and TelnetIO.readNEVariables() in TelnetIO.java:1127-1180 stores each variable pair in a HashMap held by ConnectionData, allowing an unauthenticated attacker to flood unique variable pairs before the terminating IAC SE byte and exhaust JVM heap memory with an OutOfMemoryError. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56171

SUMMARY

Exposure of private personal information to an unauthorized actor in Windows RDP allows an unauthorized attacker to disclose information over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-56171

CVE-2026-54335

SUMMARY

Feathersjs is a framework for creating web APIs and real-time applications with TypeScript or JavaScript. In 5.0.44 and earlier, the _.merge(target, source) utility exported by @feathersjs/commons recursively merges source into target by iterating Object.keys(source). When source was produced by JSON.parse and contains a __proto__, constructor, or prototype key, that key is returned as an own-enumerable property; the recursive merge then resolves target['__proto__'] to Object.prototype and writes attacker-supplied properties onto it, polluting the prototype for all plain objects in the process for the lifetime of the Node process. This issue is fixed in version 5.0.45.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…